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ABSTRACT
Amyloidosis comprises a group of diseases that occurs in five to nine cases per million patients per year worldwide irrespective 
of its classification. Although the hepatic involvement in primary amyloidosis is frequent, the clinical manifestations of liver 
amyloidosis are mild or even absent. The authors report the case of an aged man who complained of diffuse abdominal 
pain and marked weight loss and presented clinical signs of hepatopathy. Clinical workup revealed portal hypertension 
with ascites, hemorrhoids, and esophageal varices. The laboratory tests showed the cholestatic pattern of liver enzymes, 
hyperbilirubinemia, renal insufficiency and massive proteinuria accompanied by the presence of serum pike of monoclonal 
lambda light chain protein. The outcome was unfavorable, and the patient died. The autopsy findings revealed the diagnosis 
of amyloidosis predominantly involving the liver and kidneys. The bone marrow examination demonstrated the deposition 
of amyloid material associated with clonal plasma cells infiltration. The authors call attention to portal hypertension as a rare 
manifestation of primary amyloidosis. Meanwhile, this diagnosis should be taken into account whenever the hepatopathy is 
accompanied by laboratory abnormalities consistent with hepatic space-occupying lesions concomitantly with other organs 
involvement. In the case reported herein, kidney involvement was also present with renal failure, massive proteinuria with 
monoclonal serum gammopathy, what reinforced the diagnostic possibility of primary amyloidosis. 
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INTRODUCTION
Amyloidosis is a protein metabolism disorder that 
results in extracellular fibrils deposition composed of 
low-molecular-weight protein subunits with similar 
chemical, structural, and staining characteristics.1 
Amyloid deposits are related to a diversity of entities of 
varying etiologies involving several organs and systems.
AL amyloidosis and AA amyloidosis are the 
most clinically relevant types of the disease. Primary 
or AL amyloidosis occurs due to a plasma cell clonal 
disorder that results in the deposition of fragments of 
immunoglobulin light chains in several tissues.2 This type 
of amyloidosis, which is mostly found in developed 
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countries, is commonly associated with multiple 
myeloma and Waldenström macroglobulinemia.1,3 
In these cases, the mean age at diagnosis was 
65 years, and two-thirds of the patients were males.4,5 
Secondary amyloidosis is characterized by the serum 
amyloid AA and occurs more frequently in developing 
countries where it is commonly associated with chronic 
inflammatory diseases, such as rheumatoid arthritis, 
inflammatory bowel diseases, and chronic infections 
like tuberculosis and hanseniasis.6 Less frequent 
types of amyloidosis include the types called familiar, 
localized, senile, and those related to dialysis.6
The clinical features of amyloidosis vary according 
to the number and extension of the involved organs. 
Histologically, virtually every organ, such as kidney, 
heart, autonomic and peripheral nervous system, 
muscle, and skin, may exhibit any degree of amyloid 
deposition. However, while some patients may present 
only a single involved organ, others may show systemic 
involvement.5 Nonspecific symptoms, such as fatigue 
and weight loss, are the main initial complaints; 
however, the definite diagnosis is established when 
symptoms reflect the involvement of a particular 
organ.7 We present the interesting case of a patient 
that presented a rare manifestation of amyloidosis, 
namely: portal hypertension with ascites, esophageal 
varices, and hemorrhoids.
CASE REPORT
A 75-year-old man sought the medical facility 
complaining of diffuse abdominal pain, abdominal 
distension, postprandial fullness, hypersalivation, 
nausea, and frequent vomiting over the last 6 months. 
He referred some relief of symptoms with the use of 
a proton pump inhibitor and lost 10 kg of weight 
during this period. He was diagnosed with hemorrhoids 
2 months ago and has been presenting episodes of 
hematochezia since then. He denied hematemesis 
and dysphagia. His relatives referred an altered 
sleep–wake cycle and periods of fluctuating levels 
of consciousness over the past few days. His medical 
history included dyslipidemia, and a recent diagnosis of 
chronic liver disease of undetermined etiology. He was 
taking furosemide, cholestyramine, chlortalidone, and 
pantoprazole. He was a smoker (60 packs/year) and 
a social drinker. He came from an endemic region 
of schistosomiasis and his wife recently had been 
diagnosed with the intestinal form of this disease.
The physical examination revealed an ill-looking 
patient, icteric, and dehydrated. He was afebrile, his 
blood pressure was 80/60 mmHg, his pulse was a 
regular 72 beats per minute, and his room air oximetry 
was 97%. He was lucid and oriented in time and space, 
and the Glasgow Coma Scale was 15. The neurologic 
examination was normal. He had a jugular venous 
distension at 45 degrees, and lower limbs edema 
was present. The pulmonary examination disclosed 
bilateral diffuse crackles and hypophonesis of the 
heart sounds. The abdomen was distended; the liver 
was palpable until 7 cm below the xiphoid appendix 
(left liver lobe enlargement); and large ascites was 
present. The laboratory work-up is shown in Table1.
Other examinations included: ANA – HEp-2 = 1/320, 
nucleolar pattern, normal determination of complement 
fractions C3 and C4. Urinalysis showed proteinuria, 
37,000 erythrocytes/ mm3, hyaline, and granular casts, 
and 24-hour urine protein was 7 g. Hepatitis B and C, and 
HIV serologies were negative. The anti-mitochondria 
antibody was negative, and ceruloplasmin and 
copper determinations were within the normal range. 
The rectum biopsy was negative for Schistosoma sp 
eggs. The monoclonal component was identified in 
the serum protein electrophoresis as a lambda chain 
by immunofixation.
The abdominal ultrasound (US) showed an 
enlarged liver with a globular shape, and nonspecific 
heterogeneous echotexture of the parenchyma. 
The biliary system, pancreas, and kidneys were normal. 
A huge amount of free ascitic fluid and bilateral 
pleural effusion were present. The hepatic Doppler 
US showed a normal gauge of the hepatic veins with 
multiphasic hepatofugal blood flow. The portal and 
superior mesenteric veins were enlarged with reduced 
velocity hepatopetal blood flow. The upper digestive 
endoscopy disclosed small and medium caliber 
esophageal varices, hypertensive gastritis, and a healing 
duodenal ulcer. The abdominal computed tomography 
showed an enlarged liver at the expense of the left 
and caudate lobes, plus splenomegaly, and ascites. 
Doppler echocardiography showed a mild double aortic 
lesion (mean systolic left ventricular/aortic gradient of 
9 mmHg), mild diastolic left ventricular dysfunction, 
and preserved systolic function. Renal biopsy was not 
performed due to the patient’s critical clinical status. 
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A diagnostic paracentesis was undertaken and the 
results were consistent with portal hypertension 
(serum-ascites albumin gradient = 2.37 g/dL) and 
a high number of neutrophils consistent with the 
diagnosis of spontaneous bacterial peritonitis, which 
was treated with the administration of albumin and 
ceftriaxone. The patient’s condition evolved with 
persistent altered mental status, and after 2 weeks 
of hospitalization he suddenly presented thoracic 
pain with no ischemic electrocardiogram changes nor 
elevation in myocardial necrosis markers. Two days 
after this complaint he presented cardiac arrest and 
died. An autopsy was performed.
AUTOPSY FINDINGS
At gross examination, the autopsy confirmed 
general findings of portal hypertension, such as severe 
ascites (4.0 L), splenomegaly, gastric and esophageal 
varices with no signs of bleeding. The spleen (341 g; 
reference value [RV]: 112 g) and the liver (2800 g; 
mean RV: 1720 g) were enlarged (Figure 1) and had 
Figure 1. A - Gross aspect of the enlarged liver showing a slight nodular surface; B - Gross aspect of the enlarged 
spleen showing a pale cut surface and whitish fibrin deposits on peritoneal surface (bottom).
Table 1. Initial laboratory workup
Result RV Result RV
Hemoglobin 18.0 12.3-15.3 g/dL Potassium 4.9 3.5-5.0 mEq/L
Hematocrit 52.6 36.0-45.0% Sodium 142 136-146 mEq/L
Leukocytes 8,090 4.4-11.3 × 103/mm3 ALT 49 9-36 U/L
Segmented 53 45-70% AST 87 10-31 U/L
Eosinophils 1 1-4% ALP 1106 53-128 U/L
Basophils 0 0-2.5% γGT 788 2-30 U/L
Lymphocytes 36 18-40% Amylase 102 30-118 U/L
Monocytes 10 2-9% Lipase 100 13-60 U/L
Platelets 351 150-400 × 103/mm3 TB 3.0 0.3-1.2 mg/dL
INR 1.49 1.0 TP/Albumin 4.9/2.87 6.4-8.3/3.5-5.2 g/dL
Urea 165 5-25 mg/dL Ferritin 784 22-322 ng/mL
Creatinine 3.57 0.4-1.3 mg/dL CRP 17
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; γGT = gamma-glutamyl 
transpeptidase; INR = international normalized ratio; RV = reference value; TB = total bilirubin; TP = total protein.
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a particularly firm and waxy consistency. Despite 
showing a fine nodular capsular surface, the liver 
did not show macroscopic portal tract fibrosis or 
cirrhosis. These gross findings raised the suspicion 
of an infiltrative disease and cytological smears were 
taken from the liver and the spleen. These samples 
were curiously difficult to smear onto the slides due 
to their waxy consistency.
The smears showed abundant amorphous 
material, which was purple on May-Grünwald-Giemsa 
stain and densely orangophilic on Papanicolaou 
stain (Figure 2). Intermingled spindle cells looked 
compressed by the waxy material.
The heart was also enlarged (435 g; mean 
RV: 340 g), the kidneys had a nodular surface, and 
the cortex was pale. Renal samples were collected for 
immunofluorescence.
The histological examination showed a diffuse 
and dense deposition of amyloid, confirmed by Congo 
red staining and apple-green birefringence under 
polarized light in several organs. The liver and the 
spleen showed massive and compressive sinusoidal 
deposition (Figure 3). Small vessels were also affected, 
particularly some hepatic veins. The heart showed 
moderate diffuse interstitial deposition and some 
vascular amyloid deposition. Also, a focus of organizing 
thrombosis was detected in the myocardium (Figure 4).
The kidneys showed diffuse mesangial glomerular 
amyloid deposition. The cortical interstitium showed 
fibrosis and interstitial hyalinization with some 
peritubular and capillary amyloid deposits (Figure 5). 
The tubules were atrophic with hyaline cylinders. 
Immunofluorescence showed a weak reaction for 
immunoglobulin A (IgA) and kappa light chain in 
the mesangium and tubules. Lambda light chain 
fluorescence was moderate, global, and diffuse in 
glomerular mesangium, and focal in the interstitium 
and vessels. Immunofluorescence was negative for IgG, 
IgM, C1q, C3, and fibrinogen.
The bone marrow showed moderate amyloid 
deposition and increased cellularity, which was 
mainly due to granulocytic proliferation, but also 
due to an increased plasma cell count. Erythroid and 
megakaryocytic cell series were preserved. Plasma cells 
were generally typical, isolated, or in small clusters, and 
made up about 10% of the bone marrow nucleated 
cells. These cells were positive for Epithelial Membrane 
Antigen (EMA) and focally for CD138, and negative for 
CD56 and cyclin D1. Kappa and lambda light-chains 
were detected in a proportion of 1:1, which was 
consistent with a monoclonal lambda plasma dyscrasia 
(Figure 6). A small component of reactive CD20+ B and 
CD3+ T lymphocytes were detected. These findings 
were consistent with primary AL amyloidosis with 
multiorgan clinical manifestations related to a bone 
marrow plasma cell dyscrasia.
Figure 2. Photomicrography of smears. A, B - Liver and spleen, respectively, showing amorphous and dense 
orangophilic material (amyloid). The spindle cells in B (stromal and lymphocytes) are compressed by the amyloid. 
Papanicolaou stain (400X in A and 200X in B).
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Minor amyloid deposition was also detected in the 
tongue, thyroid, lungs, lymph nodes, pancreas, and 
venules and capillary vessels in the bowels. A previous 
rectal biopsy was reviewed and no amyloid deposition 
was detected retrospectively.
DISCUSSION
We present the case of a 75-year-old man with 
AL lambda light-chain amyloidosis with systemic 
involvement associated with plasma cell dyscrasia, the 
diagnosis of which was made at the autopsy. The liver 
and kidneys were the most involved organs, and the 
prevailing symptoms were hepatic failure, portal 
hypertension, and nephrotic syndrome. The patient 
presented hepatomegaly, altered canalicular hepatic 
enzymes (alkaline phosphatase and gamma glutamyl 
transpeptidase), increased prothrombin time, jaundice 
associated with portal hypertension confirmed by 
the presence of ascites (with high serum-ascites 
albumin gradient), esophageal varices, hemorrhoids, 
hepatic encephalopathy, massive proteinuria, 
hypoalbuminemia, and renal failure.
Amyloid deposits in the liver are reported to be 
present in up to 54% of patients with AL amyloidosis.8 
This rate is considered to be underestimated because of 
the lack of liver biopsy in all cases. However, autopsy 
series show that hepatic amyloidosis may be present 
in up to 96% of the AL amyloidosis cases.9-11
The clinical features of hepatic amyloidosis 
are generally mild. Hepatomegaly and alkaline 
phosphatase elevation are the most common findings. 
Figure 3. Photomicrography. A - Portal and periportal amyloid deposition in the liver (H&E, 100X); B - Sinusoidal 
deposition with obliteration of hepatic vein (H&E, 100X); C - Remnant lymphoid follicle in the spleen with diffuse 
sinusoidal amyloid deposits (H&E, 100X); D - Detail of splenic amyloid substitution (H&E, 400X).
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Figure 4. Photomicrography of the myocardium. A - Interstitial amyloid deposits (H&E, 400X); B - Focal organizing 
thrombosis in a small artery (H&E, 200X).
Figure 5. Photomicrography of the kidneys. A - Diffuse glomerular mesangial amyloid deposits (H&E, 400X); 
B, C - Congo red staining 200X and 400X, respectively; D - Apple-green color of Congo red staining under polarized 
light (original magnification 200X).
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However, weight loss may be present in 72% of cases, 
fatigue in 60%, abdominal discomfort in 53%, and loss 
of appetite in 26%.11-13 Hepatomegaly may be present 
in 57-83% of patients and does not relate to the 
amount of the amyloid deposition.14,15 Less frequent 
symptoms include early satiety, edema, anorexia, 
nausea, ascites, purpura, splenomegaly, and spiders. 
Cholestatic jaundice, although rare, is associated with 
poor prognosis.12
Portal hypertension is a rare complication of 
hepatic amyloidosis16-18 and seems to be related to 
reduced sinusoidal lumen and increased resistance 
to blood flow due to massive perisinusoidal amyloid 
deposits.18,19 Mortality reaches 80% when esophageal 
varices bleeding occurs.20 The presence of ascites is 
found in 10-20% of the cases and is generally due to 
heart failure and/or nephrotic syndrome rather than 
portal hypertension.21-23 Our patient concomitantly 
presented nephrotic syndrome, but the serum-ascites 
albumin gradient was high (2.37 g/dL), which is 
consistent with ascites of portal hypertension origin.
In hepatic amyloidosis, the hepatic enzymes work 
up frequently shows an increase alkaline phosphatase 
determination as the hallmark alteration.11 In a series 
of 98 patients with hepatic amyloidosis, the increment 
of this enzyme was present in 86% of cases; 61% 
of them showed dosages above 500 UI/L. Aspartate 
aminotransferase was increased (two times the upper 
limit of the RV) in 37% of the patients.11
At admission, our patient presented nephrotic 
proteinuria associated with renal function impairment. 
Indeed, the kidney is the organ mostly involved in AL 
Figure 6. Photomicrography of bone marrow. A - Interstitial deposits of amyloid (H&E, 200X); B - Increased 
population of plasma cells (H&E, 400X); C, D - Kappa and lambda plasma cells, respectively, showing a clonal 
expansion of lambda plasma cells (kappa and lambda light chains immunohistochemistry; 40X).
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amyloidosis. The amyloid fibrils may be deposited 
either in the glomeruli as in the arteries, veins, tubules, 
and interstitium. Proteinuria ranges from a mild to a 
massive amount and is present in 70-75% of the cases; 
one-third of patients present nephrotic syndrome and 
20% of them evolve to end-stage renal disease.4,24 In a 
study comprising 145 patients25 with biopsy-proven 
AL amyloidosis, the patients with renal disease 
presented the lambda light-chain in the proportion 
of 12:1, while in the patients without renal disease 
this proportion was 4:1. Furthermore, among the 
84 patients with renal amyloidosis, those with lambda 
light-chain presented higher proteinuria (7 g/24 hours) 
in comparison with the patients whose light-chain 
was kappa (3 g/24 hours). In this study, the lambda 
light-chain amyloid seemed to be more nephrotoxic 
than the kappa. The magnitude of proteinuria and 
the renal failure were the limiting factors for survival 
in the patients with AL amyloidosis.25,26
The cardiac involvement, found in 60% of the 
patients with amyloidosis, was also present in our 
patient but with less clinical relevance. Characterized 
by interventricular septum and free ventricular wall 
thickening;27 this involvement resulted in diastolic 
dysfunction and heart failure. Our patient presented 
jugular venous distension and diastolic myocardial 
dysfunction, which could be explained, even mildly, 
by the cardiac involvement. The atypical chest pain 
presented 2 days before the patient’s death–although 
it was not accompanied by myocardial necrosis markers 
nor any electrocardiographic ischemic changes–may 
be interpreted as being of ischemic origin, in the light 
of the findings at autopsy, and may have contributed 
to the cause of death. Sudden death, syncope 
secondary to arrhythmias or bundle branch block, 
as well as angina pectoris, and myocardial infarction 
due to amyloid deposits in coronary arteries are also 
manifestations of cardiac amyloidosis.28
The International Myeloma Working Group 
formulated the diagnostic criteria for AL amyloidosis, 
requiring the presence of all of the following: (i) the 
presence of an amyloid-related systemic syndrome; 
(ii) positive amyloid staining by Congo red staining 
in any tissue or the presence of amyloid fibrils by 
electronic microscopy; (iii) evidence that amyloid is 
light-chain-related established by direct examination 
of the amyloid; and (iv) evidence of plasma cell 
proliferative disorder.29,30
The presence of plasma cell dyscrasia may be 
demonstrated by the presence of the serum or urinary 
M protein, abnormal serum free light-chain, or clonal 
plasma cells proliferation in the bone marrow.24,29,30 
The diagnosis of plasma cell myeloma could be 
based on the presence of M-protein in the serum in 
the setting of myeloma-related end organ damage 
(amyloidosis) and bone marrow monoclonal plasma 
cell proliferation. According to WHO classification, 
the amount of clonal plasma cells in bone marrow of 
multiple myeloma patients usually exceeds 10%, but 
no minimal level is designated, since 5% of patients 
with symptomatic myeloma have less than 10% 
marrow plasma cells. Thereafter, in the setting of 
myeloma-related end-organ damage with M-protein in 
the serum or urine, the diagnosis of multiple myeloma 
can be made even with less than 10% of clonal plasma 
cells in the bone marrow.31 However, other typical 
findings of multiple myeloma as hypercalcemia, anemia 
and bone lesions were lacking. In the case reported 
herein, the serum protein electrophoresis depicted the 
presence of a monoclonal spike identified as lambda 
light-chain by the immunofixation technique. Indeed, 
the lambda light chain is responsible for 75% of all 
cases of the AL amyloidosis, while the kappa light chain 
occurs in 25% of cases, and biclonality in 5% of cases, 
as observed in the series (121 cases of AL amyloidosis) 
of Palladini et al.32
The definite diagnosis of amyloidosis requires 
histological confirmation. The kidney or hepatic biopsy 
will render the diagnosis in 90% of cases; however, 
this invasive procedure has inherent non-negligible 
complications. The reason why it was not performed 
in our patient was because of his poor clinical status 
and the increased risk of bleeding.
The mean survival time of the patients with AL 
amyloidosis ranges between 12 and 18 months4,33 and 
is even smaller when associated with multiple myeloma. 
The hepatic involvement34 decreases the survival time 
to between 10 and 14 months, the association with 
portal hypertension to 8-9 months,11 and the presence 
of cholestatic jaundice to 3-5 months.12,34 Renal failure 
and restrictive cardiomyopathy are frequently related 
to the cause of death.15
Since the hepatic involvement is not the 
predominant form of presentation of AL amyloidosis, 
it is important to consider this diagnosis in a patient 
with hepatomegaly of unknown cause, and even 
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more the pattern of bilirubin, ALT, AST, ALP, and 
γGT abnormalities in this case is classic for hepatic 
space-occupying diseases as sarcoidosis, metastases 
or amyloidosis. Furthermore, the involvement of other 
organs, such as the kidney, heart, autonomic and 
peripheral nervous system, muscle, and skin should 
always be evaluated. In our case, the presence of renal 
function impairment, massive proteinuria, and serum 
monoclonal gammopathy reinforced the diagnostic 
possibility of primary amyloidosis.
This case was very puzzling because the clinical 
features were suitable for other frequent diagnoses, 
and (i) the electrophoresis result was not available while 
the patient was alive; (ii) the echocardiogram did not 
depict the described granular sparkling appearance of 
the thickened cardiac walls; and (iii) the rectal biopsy 
lacked amyloid deposition. During hospitalization, 
the main diagnostic hypothesis remained on the 
hepatosplenic schistosomiasis with portal hypertension 
associated with glomerular complications related 
to the parasite immune response. Favoring this 
hypothesis, our patient came from an endemic region 
of Schistosoma mansoni and had a familiar history of 
this diagnosis. Further investigation, unfortunately, was 
hampered by the patient’s clinical status. The autopsy 
was fundamental for the precise diagnosis of this 
case, showing the outstanding value of this study for 
teaching purposes, quality control of medical care, and 
reliability of the death certificate.
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